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INTRODUCTION 
 
          Chronic myeloid leukemia known as chronic myelogenous 
leukemia, chronic granulocytic leukemia is clonal disease that results from 
an acquired genetic change in a pluripotential haemopoietic stem cell. This 
altered stem cell proliferates and generates a population of differentiated 
cellsthat gradually displaces normal haemopoiesis and leads to greatly 
expanded total myeloid mass. One important landmark in the study of 
CML was the discovery of the Philadelphia chromosome in 1960; another 
was the characterization in the1980s of the BCR–ABL chimeric gene and 
associated oncoproteinand a third was the demonstration that introducing 
the BCR–ABL gene into murine stem cells in experimental animalscaused a 
disease simulating human CML. 
Until the 1980s, CML was generally assumed to be incurable and 
Was treated palliatively – in the early days with radiotherapy, 
And more recently with alkylating agents, notably busulphan. CML 
Can be permanently eradicated in the majority of patients who 
Survive after haemopoietic stem cell transplantation (SCT), but 
The proportion of patients eligible for SCT is still relatively small. 
The introduction into clinical practice of imatinib in 1998 was 
An important therapeutic advance, as with this agent most patients 
Achieve a complete cytogenetic response and may expect prolongation 
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of survival compared with other methods of treatment Epidemiology, 
etiology and natural history : The incidence of CML appears to be constant 
worldwide. Itoccurs in about 1.0–1.5 per 100 000 of the population 
perAnnum in all countries where statistics are adequate. CML is rarebelow 
the age of 20 years 
But occurs in all decades of life, with a Median age of onset of  
50–60 years. The incidence is slightly higher in males than in females. 
The risk of developing CML is slightly but significantly Increased by 
exposure to high doses of irradiation, as occurred in survivors of the atomic 
bombs exploded in Japan in 1945, and inpatients irradiated for ankylosing 
spondylit is but, in general, almost all cases must be regarded as ‘sporadic’ 
and no predisposing factors are identifiable. Clinically, CML is biphasic or 
triphasic disease that is usually diagnosed in the initial ‘chronic’, ‘indolent’ 
or ‘stable’ phase and then spontaneously evolves after some years into an 
advanced phase, which can sometimes be subdivided into an earlier 
accelerated Phase and a later acute or blastic phase. 
     There has been much debate about the duration of disease before 
the diagnosis is established, a question that is essentially unanswerable. If 
It is assumed that the disease starts with a ‘transforming event’ 
occurring in a single stem cell, it could be 5 –10 years before the 
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Disease becomes clinically manifest. This estimate depends onassumption 
that the leukocyte doubling time in the prediagnosis Phase is not 
fundamentally different from the doubling time after diagnosis  
and the observation that the latent interval between exposure to irradiation. 
From atomic bombs and the earliest identifiable increased incidenceof 
CML was about 7 years. One study concluded that routine blood count  
might have identified CML on average 6 Months before it was actually 
diagnosed in individual patients. Patients are usually in the ‘chronic’ phase 
when CML is diagnosed. This chronic phase lasts typically 2–7 years but it 
May seen in rare cases, last more than 15 or even 20 years. Even more 
Rarely, spontaneous remissions have been described. In about 
one-half of cases the chronic phase transforms unpredictably 
And abruptly to a more aggressive phase that used to be referred 
to as ‘blastic crisis’ and is now usually described as acute or 
blastic transformation. In the other half of cases, the disease 
evolves somewhat more gradually, through an intermediate phase 
described as ‘accelerated’ phase, which may last for months or 
Years, before frank blastic transformation supervenes, which 
May have myeloblastic or lymphoblastic features. Occasional 
Patients have a disease that progresses gradually to a myelofibrotic 
orosteomyelosclerotic picture that is characterized by extensive 
M a r r o w  f i b r o s i s  a n d  s o m e t i m e s  g r o s s  o v e r g r o w t h  o f 
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Bonytrabeculae; the clinical problems are then usually due to 
Failure of haemopoiesis rather than to blast cell proliferation, but 
a predominantly blastic disease can still supervene. The duration 
of survival after onset of transformation is usually 2–6 months. 
Chronic myeloid leukemia is a common proliferative disorder of myeloid 
series results in leucocytosis,basophils,immature granulocytes, anemia, 
thrombocytosis and splenomegaly. In hematopoetic stem cell BCR-ABL a 
fusion gene formed from reciprocal translocation of chromosome 9 and 22.  
    Tyrosine kinase inhibitors belongs to molecular targeted 
therapies .Acts by blocking the signaling pathways which helps in 
modulatingoncogenesis. Targets include anti angiogenic properties and 
vascular properties against VEGFR, PDGFR, RET, KIT which are 
involved in tumor formation. Multi targeted therapies include sunitinib, 
imatinib, sorafinib, motesanib are tyrosine kinase inhibitors Targeted at 
different sites of BCR ABL gene. 
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AIMS AND OBJECTIVES 
 
          To investigate the effect of tyrosine kinase inhibitors on thyroid 
function. 
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REVIEW OF LITERATURE 
 
Chronic myeloid leukemia is the first malignancy in humans with a 
specific Genetic lesion, BCR-ABL oncogene harbored by Philadelphia 
chromosome. Since then, it is known for discovery of targeted therapeutics 
and molecular mechanisms in field of hematological malignancies. 
Chronic myeloid leukemia resulted as acquired genetic change in a 
pleuripotent haemopoietic stem cell. This altered stem cell “ proliferates 
and generates a population of differentiated  cells  that  gradually   
displace normal  haemopoiesis and leads to increase  expansion of  total   
myeloid mass. In the study of CML, the first most important discovery is 
Philadelphia (Ph) chromosome in 1960. Secondly, description of   
BCR–ABL chimeric gene and oncoprotein in 1980. Thirdly, In 
experimental animals, introduced an  BCR-ABL gene in to the Murine 
stem cells Whichstimulated  Chronic myeloid  leukemia. 
 
    As it is a clonal hematopoietic stem cell disorder. Accumulation of 
mature myeloid cells in blood and bone marrow progressively. Due 
toBCR-ABL1 chimeric gene product, which is an active tyrosine kinase, 
resulting inreciprocal translocation between the long arms of 
chromosomes9 and 22 t(9;22) (q34;q11).  
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          Cytogenetically detected as the Philadelphia chromosome. 
CML constitutes 15% of all cases of leukemia. Male:Female ratio is 
1.6:1 Reportedas Male predominance.DiagnosisOf CML median age  
Considered as 55 to 65 years.CML is Less common in children; 
accounts 3% of patients below 20 years. Incidence of CML slowly 
increasing with age. Peak incidence increases after the 40 to 50years 
Ofage. In CML annual incidence is 1.5 cases per 100,000 individuals.  
           
          Multiple studies shows that the incidence of CML over 
several decades has not changed. In worldwide, Incidence was reported 
about 100,000 cases annually. Almost all cases must be Considered as 
‘sporadic’, in which predisposing factors are not identified .In 
particularly, there is no familial predisposition and no definite 
association with HLA genotypes.An infectious agent has no 
contribution in etiology. No increase risk inmonozygotic twins.Etiologic 
agents Such as benzene fertilizers, insecticides, viruses, secondary to 
chemotherapy of other malignancies, radiation and other toxins are also 
not associated with etiology of CML.   
 
         It has reported that ionizing radiation exposuresin nuclear 
accidents, Malignancies like Cervical cancer those are treated with 
radiation. Rheumatologic condition like few cases of ankylosing 
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spondylitis treated with radiation therapy has increased the risk of CML, it 
is related to 5–10 years of exposure and also it is dose-related. Median age 
of exposure reported as 6.5yrs.Among  survivors  of atomic bomb 
explorers in Japan 1945, Risk of developingCMLIs slightly increased. 
Chronic  myelogenous  leukemia   include   “BCR rearrangement - 
positive CML, Chronic monocytic leukemia, chronic myelomonocytic 
leukemia, chronic eosinophilic leukemia,  juvenile myelomonocytic  
leukemia and chronicneutrophilic leukemia.” 
 BCR rearrangement-positive CML indicates increased 
granulocytosis, Anemia,large proportion of mature neutrophils, 
splenomegaly more commonly, normal or elevated platelet counts, and 
absolutebasophilic. The hyper cellularmarrow contains 90% of 
Philadelphia chromosome by cytogenetic analysis. By molecular 
diagnosticanalysis, BCR gene on chromosome 22 is rearranged in 95 % of  
cases approximately. 
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“ABL proto-oncogene, an non-receptor tyrosine kinase,  located on 
chromosome 9 was translocated to chromosome 22. The positions of the 
genomic breakpoint on chromosome 22 in different CML patients”. 
Translocation of Ph causing 5′- sequences from   BCR  gene  juxtaposed 
with  3′-ABL Sequence which is derived from chromosome 
9 .Transcription  of  BCR-ABL, an  8.5kbm RNA  encoding   protein  
which has molecular Weight of 210 KDa. Tyrosine kinase activity is  far  
more  in  p210 BCR-ABL  Compared to normal ABL gene product. 
BCR–ABL transcript has two variants.  It depends on break in introns 
between the exons e13 and e14 of which results in e13a2 mRNA junction 
or break in intron between the exons e14 and e15 of which resulted in 
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e14a2 mRNA.  
 In CML Patients, the transcription of BCR-ABL  has no significant 
prognosis. Expression of ABL–BCR gene der9q location constitute 70%. 
prognosis does not depend on  expression present or absent.BCR–ABL 
gene formed from thefusion of the BCR gene first exon with the ABL gene 
Second exon.Though, B-cells , NK cells,  Tcells have BCR-ABL  and Ph 
chromosome butmost  Of  the  Bcells  and  all  Tcells progenitors of 
leukemic clone undergo apoptosis leaving behind unaffected cells. 
 
 Colony forming cells of positive Ph chromosome binds  to 
Fibronectin is less compared to normal.  Due to Modification of CD15 
antigens resulted in p-select in binding to receptors in CML Granulocytes. 
In the BCR Gene of first intron, genomic break point occurs in 2/3rd of 
patients with Ph positive ALL patients. In very rare instances, Ph 
chromosome found to be associated with chronic neutrophilic leukemia 
and instead of P210, In CML Patientsp190 Protein is present. Experimental  
studies showed that when BCR-ABL gene has cloned and introduced in to  
Retroviral vector, in Which this vector transfected into Murine 
Hematopoietic stem cells and these stem cells have produced a disease  in 
mice which Mimics CML. Pathogenesis include Autophosphorylation of 
intracellular proteins. Like crkl, Mek1/2, Racand Jnk  Where  this  
mechanism does nothappens normally. Due to activation of intracellular 
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proteins results in signal transduction pathways  of  STAT,  RAS. 
Another mechanism, P13 kinase- AKT pathway stimulation resulted in 
Apoptosis. Thus in targeted stem cells programmed cell death activated by 
BCR-ABL gene. 
 
 
 
 
 
STAGING OF CML: 
1. CHRONIC  PHASE 
2. ACCELERATED  PHASE 
3. BLAST  PHASE 
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 Mostly, Patients with chronic phase of CML diagnosed as an 
incidental finding. 
Natural history of disease:  
 Begins typically in a chronic phase 
 Progress to accelerated phase after few years   
 Finally blast crisis 
 Terminal phase of CML is Blast crisis and it behaves as an acute 
leukemia. 
 Pathogenesis of progression: From chronic phase to blast crisis is 
abnormality of new chromosome including Ph chromosome. 
 
CHRONIC PHASE: 
 At the time of diagnosis, most of the CML patients are in chronic 
phase which accounts 85% of the patients. Many of the patients are 
asymptomatic and only few have fatigue, decrease apetite, abdominal pain 
and joint pains. chronic phase of CML has variable duration. it also 
depends on  early diagnosis. treatment to be  started immediately after 
the diagnosis. if the treatment delayed then progression to accelerated 
phase  will  increase. 
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ACCELERATED PHASE: 
 Most widely used for the accelerated phase is WHO criteria 
• In Bone marrow or blood :myeloblasts 10-19% 
• In  bone marrow or blood : basophils  >20% 
• Not related to therapy: Platelet count <100,000 
• Cytogenetic evolution with new chromosomal  abnormalities 
• Not responsive to therapy: Increasing white blood cell count 
• Splenomegaly. 
 Significance of the accelerated phase is that progression of the 
disease is increased where probability of transforming to blast crises 
increases. Effectiveness of drug therapy has reduced in the advanced 
stages. 
 
BLAST CRISIS: 
 In blood or bone marrow:>20% lymphoblasts or myeloblasts 
     In bone marrow biopsy: Large clusters of blood cells presents 
     Presence of Chloroma 
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CLINICAL SIGNIFICANCE 
Loss of weight 
Fatigue 
Early satiety 
Weakness 
Nausea 
Night sweats 
Left upper quadrant pain 
Fullness in abdomen 
Fever 
Anemia    :    dyspnea, palpitation, giddiness 
Leucopenia   :   infection 
Thrombocytopenia :  bleeding manifestation. 
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  As a result of severe thrombosis or leucocytosis results in  
cerebrovascular accidents, venous thrombosis, myocardial infarction, 
venoocclusive disease,  pulmonary insuffiency, visual disturbances.  
Patients have poor prognosis if associated with positive BCR/ABL 
p230.Nearly about 10 to 15% of patients have presented with accelerated 
phase or blast crisis. Most common finding in CML is mild to moderate 
splenomegaly, but Massive splenomegaly or persistent splenomegaly 
indicates the sign of accelerated phase. Rarely sarcoma of myeloid series 
and Lymphadenopathy indicate late course of the disease; the prognosis 
will be bad. 
 
 INVESTIGATIONS: Complete blood picture shows white blood 
cell counts increased with elevation of  both mature and  immature 
granulocytes. Less than 10% and less 5% circulating blasts are present 
along with band forms, myelocytes, metamyelocytes and promyelocytes.  
Platelet counts are elevated at the time of diagnosis, and Anemia of 
normocytic normochromic are usually present. Low alkaline phosphatase 
in leucocytes are present. serum uric acid levels are elevated, Serum 
vitamin B12 and binding proteins are increased. Basophil counts are also 
increased causing pruritis, flushing and diarrhea due to histamine release in 
later stages.1 “Disease acceleration is defined by the development of 
Increasing degrees of anemia unaccounted for by bleeding or therapy; 
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cytogenetic clonal evolution; or blood or Marrow blasts between 10% and 
20%, blood or marrow basophils 20%  or platelet count <100,000/L.”  
 
 
 
“
1Blast crisis is defined as acute leukemia, with blood or marrow 
Blasts20%. Hypo segmented neutrophils may appear” 
 
 The hematological picture in acceleration is very variable. It may 
differ little from chronic phase but blast cell numbers may be increased 
disproportionately. There may be anemia in the presence of a normal 
leukocyte count. Platelet numbers may be greatly increased (1000 × 109/L) 
or reduced (Below 100×109/L) in a manner not accounted for  treatment. 
The marrow also shows a picture no longer consistent with chronic-phase 
disease, often with increased numbers of blast cells or promyelocytes and 
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increased fibrosis. Blastic transformation is defined by the presence of 
more than30% blasts or blasts plus promyelocytes in the blood or marrow 
In accelerated phase of  CML patients, transformation to control  blood 
counts is poor with  interferon or myelo supression. In peripheral blood 
smear, thrombocytopenia and basophilia not associated with therapy, 
presence of myelofibrosis, splenomegaly and new cytogenetic 
abnormalities. 
 Their morphologyis very variable. About 70% of patients have 
blasts classifiable generally as myeloid, which resemble to a degree the  
Cells that characterize acute myeloid leukemia. Such cells may 
predominantly myeloblastic, monoblastic, erythroblastic megakarocytic, 
and blast cells of different my eloid lineages frequently co-exist. These 
cells are best defined by their cytochemical and immunophenotypic 
characteristics. 
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MARKED LEUCOCYTOSIS WITH GRANULOCYTE LEFT 
SHIFT 
 In CML mixed basophilic mast cell granulation as well as 
eosinophilia present but does not have significance for diagnosis. The 
picture is similar to leukemia and it should be confirmed by bone marrow 
biopsy. 
   Bone marrow examination helps to differentiate CML from reactive 
process and other CMPDs. Bone marrow is hypercellular, due to 
neutrophilic precursor proliferation to segmented neutrophils of 
myeloblasts. High count of Myeloblasts seen in peripheral smear and Bone 
marrow. In CMPDs Morphology at each stage and maturation sequence is 
normal. There are less than 5% of myeloblasts present in marrow. 
precursors are situated in periosteum normally. whereas eosinophils, 
hybrid cells, basophils and its precursors are present even in peripheral 
smear. 
• Ph chromosome  
• BCR-ABL mutation 
• Hyper cellular marrow with expansion of neutrophils, eosinophils, 
basophils of myeloid cell line and its progenitors  
• Increase in Megakaryocytes  
• reticulin stain indicates mild fibrosis 
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   Relationship between the CD61+ megakaryocyte number and  its 
precursors with more fibrosis. Megakaryotes are increased but not as seen 
in essential thrombocytosis. Cluster of three or more groups are present in 
inter trabecular regions. Depends on number of megakaryocytes, it is 
divided as megakaryocytic CML where large number of megakaryotes are 
present. In common CML, the megakaryocytes are normal, decreased or 
increased. but this division have no clinical significance. About 1/3rd of 
patients have macrophages with Periodic acid Schiff positive, coarse, 
granular and cytoplasmic content like pseudo gaucher cells. These 
inclusions are formed from granulocyte cell membrane due to increase turn 
over of lipids. There are 3 types gray green birefringents, blue sea blue non 
birefringents, sea blue histiocytes. Staining by Prussian blue for detecting 
in macrophages for iron stores and it is founded that it is decreased 
compared with general population. Erythroid precursors in bone marrow is 
increased but sometimes it may decrease or normal. Anyways the ratio 
between myeloid to erythroid ratio is increased. By PAS or reticulin, 
connective tissue is not detected in marrow. Though, in myelosclerosis the 
fibrils of connective tissue number and thickness has been increased in 
marrow. Association with anemia, massive splenomegaly, increased blast 
cells in peripheral smear and karyotyping abnormality. 
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A 
SMALL HYPOLOBATED MEGAKARYOCYTE 
 
 For diagnosing CML confirmation is obtained by cytogenetics by 
showing t(9; 22)(q3.4;q1.1)and BCR-ABL transcripts by reverse 
transcriptase polymerase chain reaction (RT-PCR). In Cytogenetics, 
through the metaphase of marrow cell, the chromosome banding analysis 
is confirmed. If marrow cells cannot be obtained, CBA can be substituted 
by interphase fluorescence in situ hybridization of blood cells, using dual 
color, dual fusion probes that allow the detection of BCR-ABL+ nuclei. 
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           CBA required to detect chromosomal analysis. 
 
 FISH is required in detection of translocation variants. In peripheral 
blood or marrow, RNA identified by Qualitative RT-PCR. BCR-ABL 
protein weight (P210, rarely P230 or P190) identifies the transcript type, 
either e13a2 or 14a2 or very rarely e1a2, or e19a2, which accounts the 
BCR-ABL protein weight P210 . Real time, quantitative, PCR (RT-Q-PCR 
measuring BCR-ABL ) will be necessary only for monitoring the response 
to treatment.  
     Definitive diagnosis and follow up depends on Ph chromosome and 
BCR-ABL fusion gene. Immuno histochemistry is not specific for 
diagnosis because it can’t distinguish CML from Leukamoid reaction. 
there is positive CD15,CD13 and CD33 and Myeloperoxidase expect blast 
crisis. 
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 “Flow cytometric scatter gram displaying leukemic myeloid blasts 
co expressing both myeloid (CD33) and B-cell (CD19) markers from a 
case of AML complicating CML. B and C. Blood smear showing blasts 
and increased platelets and myeloperoxidase stain (C) highlight an Auer 
rod in one of the myeloid blasts”. 
 The ultimate diagnosis in CML Is FISH. 
 If BCR-ABL gene not identited through FISH. Then exclude the 
diagnosis of CML and Consider Myelodysplastic syndrome. If WBC Less 
than 50000 and no splenomegaly then consider leukamoid reaction. In 
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peripheral blood, presence of myeloblastsexclude leukamoid reaction as 
diagnosis. Bone marrow shows prominent Myeloid dysplasia . 
 
 
 
 Southern blot analysis Identifies rearranged BCR gene. Western blot 
analysis Identifies BCR-ABL gene. Fusion gene in nuclei of metaphase 
and interphase identified by FISH technique. Investigation of choice for 
intial diagnosis and it helps in diagnosing 100% in CML patients. 
peripheral blood and bone marrow dried smears are also identified through 
cryptic translocation. 
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The conventional karyotypingWill detect only 95% of CML patients. 
BCR-ABL fusion protein is formed as the results of chromosome 
translocation. 
 
A.BCR/ABL in FISH:  Philadelphia chromosome formed as the 
result of reciprocal translocation from Abelson gene (ABL) of chromosome 
9 with the breakpoint cluster region gene (BCR) of chromosome 
22.BCR/ABL fusion gene product at molecular level. In blood or bone 
marrow, FISH analysis will be performed on metaphase cells or interphase 
stage. At the ABL gene the probe is labeled with fluorophore red where as a 
probe at the BCR gene to be labeled with a “green’’ fluorophore. After 
DNA denaturation both red and green probes are added to patient's cells 
and  hybridization to be  done. Two yellow signals are detected as the 
results from the BCR-ABL fusion gene and the presence of BCR-ABL, 
reciprocal translocation the t(9;22) (q34;q11.2)  are formed. If at all,two 
green and two red signals are detected and ABL-BCR gene not been 
detected then it indicates that translocation has not been occurred and also 
there is no evidence of CML..B. sequences of BCR and ABL due to 
juxtaposition where as it is detected by FISH or cytogeneticsto form 
chimeric mRNA of size 210 kilo Dalton. The oncogenic fusion protein, 
BCR-ABL is transcribed by p210 and detected by RTPCR.BCR/ABL 
fusion protein Of P190 is showed by acute leukemia t(9;22), CML always 
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shows that the translocation of fusion product p210. Between exons b3, b4 
and b2,b3 as the result, breakpoint cluster region of major Part in the BCR 
gene. 
 
 The outcome is variable in CML patients. Before treatment of the 
imatinib, the median survival rate is 4 years. 10% of patients expected 
deaths are within 2 years and every yearly 20%. Several prognostic models 
are developed in order to identify risk factors in CML. Stagingsystems 
have derived from multivariate analyses of prognostic factors. 
 
 The Sokal index to be predicted by splenic size, percentage of 
circulating blasts, platelet count, cytogenetic clonal evolution and age are 
the prognostic indicators. Based on chemotherapy-treatment ,these 
systems were identified. Based on Interferon treatment, Hansford system 
was developed. It is predicted through percentage of circulating blasts, 
spleen size, percentage of eosinophils, basophils, age and platelet count.  
Hansford system was better compared to the Sokal score, it helps in 
identifying the patients with low-risk where as in the high-risk group only 
a few patients have been identified. Both the hansford and the sokal 
systems can be used in patients with treatment under imatinib. 
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 In CML, the therapeutic goal is durable and prolonged, nonclonal 
Hematopoies is, non neoplastic and the eradication the BCR/ABL 
transcript  residual cells. Therefore the goal leads to complete cure and 
remission. 
 
 Tyrosine kinase inhibitors are  first-line Treatment  for many 
patients with chronic myelogenous leukemia. More than 90% Of  CML  
patients are  Philadelphia chromosome  positive caused by chromosomal 
abnormalities. It was discovered by Janet Rowley in 1972 and therefore 
fusion between the Abelson tyrosine kinase gene at chromosome 9 and 
with the break point cluster gene at chr 22, which results in 
chimericoncogene and the active tyrosine kinase. bcrabl gene that has 
implicated in pathogenesis of CML. Multiple Compounds are developed to  
inhibit the tyrosine kinase selectively. 
 
 New form of resistance occurs as mis sense mutations with Abl 
kinase domain, Bcr-Abl over expression, increase production of  plasma 
proteins, or activation of scrfamily kinases signaling molecules in 
downstream. 
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 The Messenger RNA transcript of BCR-ABL identified by RT-PCR  
Qualitative technique but it is different to standardize. Hence quantitative 
real time PCR techniques standardization is difficult. 
 
 The conclusion reported that FISH or karyotyping is required for 
therapeutic purposes and guided as early phase of treatment. 
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 newly diagnosed CML has vastly changed in last
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 about prognosis to be obtained
 discussed at this stage, mainly for the yo
 the disease. The patient, 
 genetically HLA typed. In asymptomatic 
/L then there is no urgent to treat.
 of bloodstem cells can be cryoprecipitated before
 be used for auto graftlater. Drug therapy
is confirmed. 
 
 
. The 
unger patient 
families, 
patients, If 
 
 
 should  
  
29 
 
 The best treatment at present in chronic phase for allogeneic SCT 
introduced as imatinib, and the number of imatinib combinations are tested 
and then approved. Hydroxyureais also used in the short term if imatinib is 
notavailable. Special indications, INF alpha and busulfan are treatment of 
choice alternatively. 
 
 
 
Imatinib mesylate 
 Imatinib mesylatealso called Glivec or Gleevec; initially known as 
STI571 or CGP 57148B) and it is 2-phenylaminopyrimidine compound, it 
is an ABL tyrosine kinase inhibitor discovered in 1998.  
 It originally acts by occupying ATP-binding pocket of Abl kinase 
which is the component of onco protein BCR–ABL, and therefore the 
capacity for phosphorylation of the enzyme has been blocked. Then 
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discovered that by binding to an domain in this manner, it can holds the 
Abl component of oncoprotein BCR–ABL. 
 The drug that rapidly reverses the hematological and clinical 
abnormalities and the cytogenetic responses in more than 80% of CML 
patients in chronic phase who were not treated. The dosage was given 
orally 400 mg per day, but the pilot studies, shown that the treatment with 
600 mg or 800mg daily initially can give better results. Side-effects are 
bone pain, nausea, edema of infra orbital region, headache, rashes, and    
generalized fluid retention. The treatment for these side effects include 
interruption of imatinib temporarily from time to time. and re-instituting 
the corticosteroid coverage shortly for skin rashes. Hepatotoxicity detected 
by increasing serum SGOT and SGPT and may require to stop drug for 
some period of time. Recently reported that it may potentially causes 
cerebral oedema which may fatal. In small groups of people, reported that 
hair pigmentation and the interesting non-sinister effect. The toxicity of 
INF-alpha seems to cause comparatively less. In minority, with in few 
months of treatment with imatinib at standard dosage of 400 mg per day 
caused neutropenia andthrombocytopenia. In few cases, isolated 
neutropeniacan be managed with G-CSF at the dosage of 300–480 µg  on  
alternative days subcutaneously, after which it is possible to stop or 
decrease the  drug dosage. In other few case reports, G-CSF function is 
less comparatively. 
  
31 
 
 Therefore it is necessary to decrease the dose or to stop the imatinib. 
In case of thrombocytopenia, it is necessary to reduce the drug. daily 
dosage of 300mg  is relatively ineffective. But thrombocytos is persisted 
in patients with leucocyte count which was well controlled by imatinib. In 
such cases, hydroxyurea oranagrelide to be added which usually controls 
the platelet count. But the duration of imatinib to continue is not known. 
For those who has attained complete cytogeneticremission, for them by 
stopping the drug can lead to recurrence of Ph positivity & leucocytosis in 
majority of cases. Although sometimes, the cytogenetic remission without 
treatment for many months or longer can continues. At present, the best 
advice to the patient is that continue the drug indefinitely. Major 
cytogenetic response for the patients who has failed to response after 1yr of 
therapy is> 66% Ph negativity in the bone marrow. Reports that, Inspite of 
continuing treatment with imatinib is weak and therefore other alternative 
approaches to be considered. 
 Among patients those who achieve complete cytogenetic remission, 
BCR–ABL transcripts are low in number. And it is usually be detected by 
RT-PCR, therefore conclude that eradication of CML as a single agent 
with imatinib is difficult.  
 A prospective study of phase III trial designed randomly to compare 
imatinib as single agent with combination of cytarabine and interferon 
alpha in untreated patients previously and this study started in June 2000. 
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The results showed, Patients with imatinib treatment about 74% of patients 
had a complete cytogenetic remission than to comparision with the control 
arm. Progression-free survival with imatinib treatment is significantly 
betterthan in the IFN-αand cytarabine treated patients. Statiscally proven 
that 97.2% versus 90.3%;hence imatinib as the single agent in causing 
remission is highly significant than other combination drugs reported asP 
<0.001. 
       Imatinib have reported that overall survival has been increased. 
Residual BCR–ABL transcripts and cytogenetic responses are in low 
levels. Proved that it is the only agent as treatment of choice for almost or 
all newly diagnosed CML Patients. Monitoring the response of treatment 
with imatinib is by FISH,bonemarrow analysis and cytogenetic studies for 
the BCR–ABL gene  for patients without  any  cytogenetic remission.  
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 A)‘’ATP occupies the pocket in the ABL component of the 
BCR–ABL oncoprotein, whence it donates a phosphate (P) group to a 
tyrosine (Y) residue on an unspecified substrate. The substrate then 
detaches itself from the BCR–ABL onco protein and makes functional 
contactwith a further downstream effector molecule’’  
 “(b) imatinib occupies the ATP binding site and thereby prevents 
phosphorylation of the substrate. This molecule in turn fails to make 
contact with the effector protein and the signal transduction pathway that 
would otherwise transmit the ‘leukaemia signal’ is interrupted.” 
 The only approach is RT-PCR for BCR–ABL transcripts  to know 
the degree to recognize incipient relapse and response. As it indicates 
revised therapeutic strategy including SCT in allogenics. In patients with 
CML especially in chronic phase, acquisition to imatinib resistance is rare 
for diagnosis within the first 2 years. In patients on imatinibin ‘late chronic 
phase’ is more common than after treatment with other agents. Around 70% 
of patients those who treated during myeloid blast crisis found to have 
imatinib resistance and relapse is seen in all of those in lymphoid blast 
crisis within 6 months after initial response. Resistance is seen along with 
the variety of diverse mechanisms, including the point mutations acquired 
in the ABL kinasedomain, BCR–ABL oncoprotein, over expression and  
P-glycoprotein over expression, which increases the drug exit from 
individual cells. Thus the 20 point mutations in imatinib resistant patients 
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of variable degree have been identified in leukemia cells. The coding for 
different each amino acid substitutions in BCR–ABL oncoprotein. Cells 
with one substitution, replaced by an isoleucine with threonine at 
315position where it is referred to as T315I mutation resistant to imatinib. 
Resistance is less in Cells with other substitutions. The amino acid 
substitutions in Abl kinase domain, one particular part where the 
phosphate-binding loop so called asP-loop which predicts progression of 
disease and also the poor survival. It is probable that these sub clones 
pre-exist the administration of imatinib but are allowed to expand when the 
wild-type molecule is inhibited by imatinib. 
Hydroxyurea: 
 A ribonucleotide reductase inhibitor which targetsmature myeloid 
progenitors in the proliferative cycle. The pharmacological action is 
reversible and rapid. Treatmentin chronic phase starts with 1.0–2.0 g daily 
by oral. By treatment all the features of CML begins to reverse at the 
duration of 4 to 8 weeks .The size of the spleen reduces and wbc counts 
decreases with in few days. The hydroxyurea dose to be titrated according 
to the leucocyte count, therefore the maintenance dose is given between 
1.0 to 1.5 g daily.  
 Decrease in dose of the drug causes increase in wbc counts rapidly, a 
phenomenon which has no ominous significance. The drug has few 
side-effects. At increased dosage, it causes gastrointestinal disturbance, 
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diarrhea, nausea, skin rashes, ulcers of the buccal mucosa. Megaloblastic 
changes are seen mostly in the bone marrow and macrocytosis seen in the 
blood. This is useful in patients who are unable to tolerate imatinib and 
also in newly diagnosed patients for rapid cytoreduction. 
 
Interferon-a 
 It belongs to a member of family of glycoproteins with 
anti-proliferative and antiviral properties. In 1980s studies shows that 
human cell lines active in reducing and reversing all features of CML in 
about 70–80% of patients. Of particular interest, about 5–15% of patients 
obtained Ph-positive marrow metaphases, a major reduction with 
restoration of Ph-negative haemopoiesis. Founded that ‘cytogenetic 
responders’ have prolonged the life by treatment with IFN-α, and 
compared with hydroxyurea showed that attainment with INF-alpha is 
maximum cytogenetic remission according to randomized controlled 
studies prospectively. 
 These observations have proved that IFN-α has better role than 
busulphan and hydroxyurea in CML of chronic phase till the imatinib 
introduced as primary treatment. Administration of Interferon-α by 
subcutaneous injection ranging from 3 to 5 mega units per/m2 in daily 
doses. There is no evidence that the increased doses are beneficial. 
Toxicity is common but reversible in most of the elderly patients. Toxicity 
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includes muscle aches, fevers, chills and rigors and general ‘flu-like’ 
features by starting the drug; reduces by paracetamol but lasts for 2 to 3 
weeks. When drug dosage is increased it will again recurs but few patients 
cannot tolerate these side effects of drugs. 
 But adverse effects of drugs include wt loss, alopecia, malaise, 
lethargy, thyrotoxicosis, depression, anorexia, lethargy. An recent 
introduction of pegylated IFN-α, has advantage over conventional 
formulations. 
 
Busulphan: 
 It is an 1,4-dimethanesulphonyloxy,an alkylating agent that is not 
frequently used. It targets primitive stem cells and administration is 
prolonged after stoppage of the drug. In 1960 to 1980, it is the mainstay of 
treatment for CML. Conventionally treatment was started orally with 8mg 
daily. By using drug, wbc counts has found to be reduced. once the 
leukocyte count falls less than 20 × 109/L. It is the indication to reduce or 
stop the drug. These patients may presents with infections due to profound 
and prolonged leucopenia. Busulphan to be administered at a maintenance 
dose between 0.5 and 2.0 mg per day up to 4 weeks. Few patients were 
‘hypersensitive’ to busulphan and developed irreversible, pancytopenia 
and marrow hypoplasia with standard dosage. Gonadal failure occurs 
within a few months of treatment and was almost irreversible. In elder 
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patients dosage of drug is 50 to 100 mg orally up to 4 weeks. Other 
toxicityincludes pulmonary fibrosis, cutaneous Pigmentation and 
hypoadrenalism. 
 
Homoharringtonine: 
 Drug used in CML of chronic phase,it is ansemi synthetic plant 
alkaloid that causes apoptosis. In 60–70% patients, it causes hematological 
response and In25% of patients causes cytological responses. 
Improvement is seen with the addition of IFN-α. But it remains an 
investigational agent. 
 
Dasatinib: 
 Dasatinib is second generation tyrosine kinase inhibitor which 
targets BCR-ABL protein .As, it was developed after the imatinib, it 
iscalled as second generation TKI. Like imatinib, it is administered orally. 
 Dasatinib is used as the first treatment for CML, especially in those 
who cannot tolerate side effects of imatinib. And it was first approved to be 
taken twice daily. 
 Adverse effects includes volume overload, diarrhea, nausea, 
leucopenia and cutaneous rash. More common serious effect is 
accumulation of fluids in the lung in form of a pleural effusion. This side 
effect is seen commonly seen in patients on drugs twice daily. The 
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accumulation of fluid is recurrent even after aspiration with needle or 
intercostal drainage then it is the caution for reducing the drug dosage. 
Indication of treatment for blast crisis, accelerated and chronic phase is 
that chronic myeloid leukemia with Ph positive resistance to therapy 
including imatinib. Start 140 mg PO qDay and may increase to 180 mg q 
Day if response is inadequate’’ 
Nilotinib 
 Nilotinib known as Tasigna second generation TKI which targets  
BCR-ABL protein. In first line therapy for CML, this drug can be used. It 
is indicated in patients those who are inability to tolerate the side effects of 
imatinib drug. Nilotinib side effectsare mild to moderate, which include 
gastroenteritis nausea, vomiting, diarrhea, volume overload, leucopenia. It 
may cause hyperglycemia and pancreatitis, but this is rare. prolonged QT 
interval and paroxysmal arrthymia another side effect seen. ECG before 
and after treatment to be mandatory. It may cause sudden cardiac death. 
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Bosutinib: 
“Bosutinib is another TKI which targets the protein of BCR-ABL. US 
Food and Drug Administration has approved this drug for the treatment of 
patients who were already on another TKI Therapy.” 
Common side effects usually includes anemia, leucopenia, diarrhea, 
nausea, thrombocytopenia, rash, fever, abdominal pain. rarely drug can 
cause fluid retention, hepatotoxicity and hypersensitivity reaction.  
Ponatinib 
 Ponatinib is a new TKI which targets the BCR-ABL protein. 
Reported that this drug causes serious adverse effects.Due to this, it is used 
rarely. T3151mutation occurs in gene where patients were treated with 
TKI therapy. This mutation also prevents other TKI from its action in 
patients with CML on treatment. Therefore in such situation, the only drug 
used is ponatinib. Reported that, it is the first TKI  against CML cells who 
have T3151 mutation. Dose to be taken once daily. 
 Many of the side effects include abdominal pain, cutaneous rash, 
precoaguble states which results in Myocardial infarction, cerebrovascular 
accidents, DVT, hypertension, fatigue, headache, rash or other skin 
problems and fatigue. It is very commonly encountered in elderly patients 
and those with risk factors like hypertension, diabetes mellitus, and 
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hyperlipidemia. Other adverse effects of drug are pancreatitis,heart failure, 
hepatotoxicity, gastroenteritis. 
Allogeneic stem cell transplantation: 
 In patients of young age, Allogenic stem cell transplantation is main 
stay of treatment with siblings of identical HLA donors. Due to major 
adverse effects with SCT, patients of age above 50 to 55yrs are excluded. 
Major factors which influences survival are duration of disease, age of 
onset, phase of disease at time of SCT, gender and between donor and 
recipient degree of histocompatibility. Immunosuppressant used in 
transplantation is cyclophosphamide, irradiation and combination of high 
dose busulphan and cyclophosphamide. After infusion of hematopoietic 
stem cells of donor, with in 3 to 4 weeks the function of marrowis achieved. 
The major complications of transplantation include venooclusive disease 
in liver, infection with cytomegalovirus, graft-versus-host disease, 
idiopathic pneumonitis. The 5yrs survival rate among HLA identical 
siblings, marrow transplantation is 60 to 80% of patients Among patients 
with transplantation, relapse rate is only 15% and mortality rate 20%.  
Even very low number of bcrabl is detected by RT-PCR both in bone 
marrow and blood. Monitoring the patients with cytogenetic studies 
without evidence of hematological disease. As transplantation major side 
effect is toxicity. 
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 Many studies shows that graft versus leukemia had important role in 
eradicating the CML. New strategies shows that toxicity reduced by pre 
transplant precautions and immune suppressants. These focuses 
predominantly on the Immunosuppressive agents rather than 
myeloablation therapy.  To increase the number of transfusion of 
haemopoietic stem cells, In order to reduce the GVL effects by immune 
competent cells of donor. Non-myeloablative, mini and reduced intensity 
Stem cell transplantation. In long term, NSCTs was superior by comparing 
conventional transplants. In Molecular methods, HLA class I and II  and 
five gene pairs include HLA-A,HLA -B,HLA -C,HLA -DR and HLA-DQ. 
After transplantation allogenic SCT relapse occurs in 10 to 30%within 
3years and the relapse is Insidious in nature. It is characterized by 
increasing transcripts levels of BCR–ABL, metaphases of Ph-positive 
marrow, in chronic phase of hematological features. therefore all 
post-transplant patients should be monitored by Cytogenetic analysis and 
RT-PCR. For the Treatment for relapse includes INF-gamma, imatinib, 
hydroxyurea and transplant for second time by using another or same 
donoror transfusions of lymphocytes is mainly mediating a GVL Effect 
through the original donor. Even though leukemia eradication is difficult. 
complete cytogenetic remission occurs in 3 to 6months in 80%.Graft 
versus host disease incidence is decreased by lymphocyte transfusion for 4 
to 12 weeks it is known as escalating dose. However, imatinib is the best 
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treatment of choice. But in younger individuals stem cell transplant plays 
major role. Initial treatment should be with imatinibe for un responders an 
imatinib-containing combination to be used.  
 In antenatal patients with CML, treatment is difficult especially in 
first trimester it is better to delay the treatment including imatinib. When 
diagnosed the CML in asymptomatic patient. If needed blood transfusion 
and leucopharesis to be transfused. In second trimester, treatment include 
interferon- alpha and where as in third trimester imatinib to be given. 
 A fusion gene FIP1L1-PDGFRA in the EOL-1 cell line where 
nilotinib acts up on. It induces apoptosis and also it inhibits  
proliferation. Mechanism of action is by inhibition of the PDGFRA 
tyrosine kinase phospharylation. Resistance of imatinib is caused by the 
T674I point mutation in FIP1L1-PDGFRA. Modulation of the signal 
transduction of the tyrosine kinase results in treating diabetic retinopathy, 
angiogenesis, tumor growth, atherosclerosis, macular degeneration and 
inflammatory diseases. 
 The thyroid gland composed of thyroid follicular cells that secretes 
Thyroglobulin rich inproteinaceousfluid.Pitutary gland of anterior part 
Containsthyrotrope cells which secretes TSH.Thyroid axis is controlled by 
TSH which is used as physiologic marker of thyroid hormone. 
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 The biologic activity of TSH hormone is influenced by Thyrotropin 
releasing hormone. 
Hypothalamus secretes TRH 
 
TRH stimulates pituitary gland 
 
Pituitary gland secretes TSH 
 
TSH stimulates thyroid gland 
 
Thyroid gland secretes thyroid hormone 
 
Feed back to inhibit TRH and TSH production 
 
 In the thyroid axis, “set point” is established by TSH. Radio 
immunoassays are most useful in detecting TSH levels. these are highly 
specific and sensitive for diagnosis of hypothyroidism and 
hyperthyroidism. 
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 The thyroid gland secretes T3 and T4 by fixing and transporting 
amino acids in Thyroglobulin.  
 Depends on situations, thyroid hormones are released in the body. 
TRH signaling from hypothalamus results in TSH released from pituitary 
gland. 
• Thyroid hormones in free forms are more active than bound forms. 
• Mechanism of action is by entering in to the cells and binding to 
thyroid receptors. They alter the gene expression by transcripting 
the nuclear factors. 
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• Thyroid hormones regulates cardiac function, metabolic rate, 
mentation, calorigenesis and Synergistic action with 
catecholamines. 
  T3 is more potent and the precursor for T3 is T4.Conversion of T3 
to T4is by the deiodinase enzymes. There are two types of deiodinase 1 and 
2. Type I deiodinase, is located mainly in liver, kidney, thyroid and the 
affinity is low for T4. 
 Thyroid Hormone synthesis Thyroid hormones are derived from 
Thyroglobulin, a large iodinated glycoprotein. After secretion into the 
thyroid follicle, Thyroglobulin is iodinated on tyrosine residues that are 
subsequently coupled via an ether linkage. Reuptake of Thyroglobulin into 
the thyroid follicular cell allows proteolysis and the release of newly 
synthesized T4 and T3. 
 Iodine metabolism and transport Iodide uptake is a critical first step 
in thyroid hormone synthesis. Ingested iodine is bound to serum proteins, 
particularly albumin. Unbound iodine is excreted in the urine. The thyroid 
gland extracts iodine from the circulation in a highly efficient manner. For 
example, 10–25% of radioactive tracer (e.g., 123I) is taken up by the 
normal thyroid gland over 24 hours; this value can rise to 70–90% in 
Graves’ disease. Iodide uptake is mediated by NIS, which is expressed at 
the basolateral membrane of thyroid follicular cells. NIS is most highly 
expressed in the thyroid gland, but low levels are present in the salivary 
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glands, lactating breast, and placenta. The iodide transport mechanism is 
highly regulated, allowing adaptation to variations in dietary supply. Low 
iodine levels increase the amount of NIS and stimulate uptake, whereas 
high iodine levels suppress NIS expression and uptake. The selective 
expression of NIS in the thyroid allows isotopic scanning, treatment of 
hyper thyroidism and ablation of thyroid cancer with radioisotopes of 
iodine, without significant effects on other organs. Mutation of the NIS 
gene is a rare cause of congenital hypothyroidism, underscoring its 
importance in thyroid hormone synthesis. Another iodine transporter, 
pendrin, is located on the apical surface of thyroid cells and Type II 
deiodinase located at thyroid gland, brain, pituitary gland, brown fat and 
affinity towards T4 is high. During levothyroxine replacement regulation 
of T3 concentration is expressed by type II deiodinase. Peripheral 
conversion of T4 to T3 is increased in the pituitary. Peripheral conversion 
is decreased in conditions like oral constrast agents, systemic diseases, 
chronic disease, fasting, trauma and drugs like glucocorticoids, 
propranolol, amiodarone and propylthiouracil. Reverse T3 is formed from 
inactivation of T4 andT3 By Type III deiodinase. 
 Tyrosine kinase inhibitors are used in the treatment of solidand 
haematological tumours. Tyrosine kinases takes part in oncogenesis which 
are inhibited by these drugs. In 2005,one case have been published that due 
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to use of tyrosine kinase inhibitors in CML patients there is derrangment of 
thyroid function test and resulted in hypothyroidism. 
 Based on clinical findings,numerous hypotheses proposed that TKI 
therapy effects the thyroid function. TKI effected the thyroid hormone 
metabolism and regulation which are specific for molecule. As 
hypothyroidism caused by therapy will halt the quality of life. 
 Sunitinib also inhibits tyrosine kinases receptor, which include 
antitumor activity, antiangiogenic and receptors of vascular endothelial 
growth factor. Have been reported that sunitinib causes high frequency of 
hypothyroidism but the mechanism is unknown. 
 “overt hypothyroidism with an atrophic thyroid and a marked 
reduction in vascularity as determined by ultrasonography, despite high 
levels of thyrotropin. In contrast, during the off-periods in the sunitinib 
treatment cycles, the volume of the thyroid recovered with an increase in 
vascularity despite a low level of thyrotropin. These results suggest that 
thyroid function and volume may depend on the vascularity, which is 
negatively regulated by sunitinib. Therefore it induces hypothyroidism by 
decreasing blood flow due to capillary regression and constriction. 
 Targeted therapies are newly developed drugs which inhibit the 
tyrosine kinases activity, known for its progression in the neoplastic 
therapy.  Imatinib, an first line drug used in the chronic myeloid leukemia 
treatment and the humanized monoclonal antibody, transtuzumab against 
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the ERBB2 receptor tyrosine kinase, which has been used in breast cancer. 
It is 25% efficious. Cardiotoxicity noted as one of serious side effect which 
progress from left ventricular dysfunction to heart failure. Therefore it is 
very important to detect early features of drug adverse effects and treat 
accordingly. In young individuals it may cause irreversible injury to 
myocardium. Reported that imatinib therapy compared to nilotinib therapy, 
progression of disease is reduced with dose of 300mg to 400mg and blast 
crisis to accelerated phase. Side effects include headache and skin 
manifestations. Laboratory manifestations includes elevated Bilirubin 
levels, SGOT and SGPT but discontinuation due to these side effects are 
reported less. Therefore, comparision Between imatinib and nilotinib the 
progression, remission and side effects are beneficial with nilotinib 
therapy .Hence, the patients with Philadelphia chromosome positive the 
nilotinib is superior to imatinib. 
“Nilotinib has been shown to be a more potent inhibitor of BCR-ABL 
than imatinib. therefore evaluated the efficacy and safety of nilotinib, as 
compared with imatinib” 
 Dasatinib, an second line agent for treatment of CML. Its induces 
molecular and cytogenetic responses significantly. The improvement of 
outcome of the patient is rapid with dastinib. The response to treatment 
achieved within 12 months. Dosage of drug is once daily. 
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 The Imatinib, tyrosine kinase inhibitor, first targeted therapy for 
chronic-phase CML. Response of therapy and survival has good 
outcome.“A qualitative systematic review was conducted to qualitatively 
compare the clinical effectiveness, safety, and effect on quality of life of 
TKIs for the management of chronic, accelerated, or blast-phase CML 
patients” 
 Thyroid dysfunction in CML Ph positive patients on treatment with 
tyrosine kinase inhibitors: 
• A new class of anticancer therapy which is multitargeted acts on 
receptors of growth factors are tyrosine kinase inhibitors. These 
are indicated in treatment for gastrointestinal stromal tumors and 
renal cell carcinoma. Many studies shows that TKI causes thyroid 
dysfunction especially produced by sunitinib maleate.  
 
 Mechanisms of thyroid dysfunction include due to this side effect of 
tyrosine kinase inhibitors included are 
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• induction of thyroiditis 
• capillary regression in the thyroid gland 
• antithyroid peroxidase antibody production, and  
• Iodine uptake by the thyroid gland declined. 
 As TKI therapy causes thyroid dysfunction, it is necessary for 
follow up regularly for thyroid profile and clinically for signs and 
symptoms of hypothyroidism. If there is derangement of thyroid function 
then treatment to be started for the improvement in survival and prognosis. 
Due to adverse effects of therapy the treatment never be discontinued. 
Thyroiditis as the result of drug causing hypothyroidism. Therefore 
monitoring of TFT is mandatory. Due to tyrosine kinase receptor 
abnormality in regulation causes hematological and solid tumors. 
 
• stem-cell factor receptor - gastrointestinal stromal tumor 
• platelet-derivedgrowth factor receptor-dermatofibrosarcoma 
• protuberans fetal liver TK receptor 3 - acute myelogenous leukemia 
 
 Targets of TKI include domains of platelet-derived growth factor 
receptorα/β, mitogenactivated protein kinase/extracellular signal-regulated 
kinases, v-raf murine sarcoma viral oncogene homolog, RET, KIT And it 
inhibits the differentiation,proliferation and migration. 
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 Recently approved by the Food and Drug Administration US, are the 
Sunitinib and sorafenib. These two drugs used for advanced renal cell 
carcinoma on the phase III trials. 
 Sunitinib : approved forpancreatic neuroendocrine tumorsand   
gastrointestinal stromal tumor. 
 Sorafenib : approved for hepatocellular carcinoma 
 Hypothyroidism Incidence after intake of sunitinib is between 53% 
and 85%.  
 Effects of sunitinib as chemotherapy used in GIST(gastrointestinal 
stromal tumors) had developed in 46% of patients. and transient 
hypothyroidism Seen in sunitinib therapy after first cycle. but by the 
chemotherapy ending, there is an elevation of TSH. once after starting Off 
phase, thyroid hormone become normal. After permanent discontinuation 
of therapy, the thyroid levels with in 60 days became normal. Radiological 
changes in form of decrease iodine uptake during ON period of therapy 
and return to normal in OFF period of treatment. As the number of cycles 
increases, thyroid dysfunction increases. Reported that median time to 
develop hypothyroidism is4 weeks from the intake of therapy. Few 
patients developed permanent hypothyroidism, out of these patients there 
is requirement of thyroid hormone replacement in few patients. long term 
use of therapy is faster to develop thyroid dysfunction compared to short 
term use of therapy. Sorafenib is second line oral inhibitors of tyrosine 
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kinase, which is approved for the treatment of renal cell carcinoma by 
targeting kinases like RET, BRAF, VEGFR And also used in treatment of  
unresectable hepatocellular carcinoma, Un differentiated thyroid cancers, 
lung ca, pancreaticca, prostate ca and melanoma. Incidence ranges from 20 
to 36%.which is less compared to sunitib. 
 Imatinib, most commonly used as CML therapy. It targets tyrosine 
kinase approved for the treatment of GIST tumors, chronic myeloid 
leukemia, dermatofibrosarcoma protuberans, medullary thyroid cancer. 
Many studies shows that imatinib causes hypothyroidism only in those 
patients who are already hypothyroid. It states that thyroid dysfunction 
seen in patients with thyroidectomies previously,treatment for medullary 
thyroid carcinoma had higher incidence than compared to euthyroid 
patients and there is an need to increase the dose of treatment. 
 “Therefore reported that all patients with intact thyroid glands 
receiving imatinib had no thyroid dysfunction” Dasatinib, targets tyrosine 
kinases of second generation TKI. most commonly used in the treatment of 
CML Ph chromosome positive patients with resistance to imatinib. only 50% 
of patients developed thyroid dysfunction. only few had subclinical 
hypothyroidism 
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 Axitinib, approved for renal cell carcinoma which targets vascular 
endothelial growth factor receptors of types 1, 2, and 3.data shows thyroid 
dysfunction reported within one month of therapy. But many trails shows 
that axitinib incidence of developing hypothyroidism is more when 
compared to sorafenib. 
 Pazopanib, an second generation tyrosine kinase inhibitors approved 
for the treatment of renal cell carcinoma. it targets c-kit, platelet derived 
growth factor and VEGFR1,2,3. Incidence is less than 10% as reported. 
many studies after trails shows that few patients developed thyroid 
dysfunction in form of hypothyroidism which is common among them. 
Others developed subclinical hypothyroidism and other few developed 
hyperthyroidism.  
 Tivozanib inhibits the activation of VEGFR 1, 2, and 3.it is potent 
than other tyrosine kinase inhibitors. Incidence of developing 
hypothyroidism is more compared than  sorefinib. This drug not only 
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increases TSH levels but also T3 levels. Motesanib diphosphate and 
vandetanib are other tyrosine kinase inhibitors used in various solid tumors 
also causes thyroid dysfunction. but reports shows that it is less common 
compared to other therapy. Mostly tyrosine kinase inhibitors causes 
hypothyroidism but few studies shows that hyper thyroidism also reported. 
Most commonly in the form of thyrotoxicosis seen with treatment of 
sunitinib. Sorafinib also causes thyroid autoimmunity and hyperthyroidism 
during the course of treatment after developing overt hypothyroidism. 
 One of the mechanism for thyroid dysfunction in Sunitinib was 
destructive thyroiditis and which was confirmed by fine needle aspiration 
of thyroid gland which resulted in lymphocytic thyroiditis. It was reported 
in 40% of patients approximately during the first cycle of chemotherapy 
sunitinib, causes thyroid dysfunction by inhibition of vascular endothelial 
growth factor receptor which are expressed by thyroid follicular cells and 
regulated by TSH leads to regression of capillaries. thyroid dysfunction is 
due to decrease blood supply to thyroid resulted in damage to thyroid gland 
in about 68% of patients. Thyroid damage is due to decrease of lumen and 
ischemic supply of blood to thyroid gland through inhibition of PDGFR. 
Therefore, more potent the inhibition, more the increase in thyroid 
dysfunction. 
 Bevacizumab, an well-known human monoclonal antibody 
targeting VEGF signaling which  prevents VEGF binding  to  receptors, 
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and it is approved for  non-small-cell lung cancer ,colorectal ca,renal cell 
ca, breast ca treatment. Though it is also acting on VEGFR but incidence of 
developing thyroid dysfunction is less in comparing with tyrosine kinase 
inhibitors. Mechanism is by decreasing vascular permeability and 
vasoconstriction of micro capillaries in the thyroid gland. There is an 
protective mechanism for lower incidence due to placenta growth factor. 
PIGF protects by restoring thyroid gland vascularity. 
 Hypothesis that sunitib inhibits iodide uptake on symporters of 
sodium channels. but it is reversible mechanism at the periods of OFF 
therapy. 
 Another mechanism includes development of antibodies resulting in 
hypothyroidism. but found in only few patients with high TSH levels. 
Sorafenib causing thyroid dysfunction is due to inhibition ofTSH signaling 
pathway, RAF pathway, PDGFR and VEGFR pathways. “Studies shows 
that patients developing thyroid dysfunction might tend to have their 
cancer better controlled through the common antiangiogenic effects 
affecting both the tumor and the thyroid” 
 Many of the tyrosine kinase inhibitors developed thyroid 
dysfunction during the first cycle of chemotherapy. Data is lacking 
whether to start thyroid replacement therapy in hypothyroidism patients or 
not. As per endocrine journals, thyroxine replacement to be given when 
TSH is above 10U/L. few data shows that there is improvement in 
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hypothyroid symptoms after intake of levothyroxine. Others approved that 
hypothyroidism is beneficial in term of survival and prognosis in patients. 
Thus, many studies proposed that TKI causes hypothyroidism by assuming 
the mechanism where few causes hyperthyroidism. Monitoring thyroid 
profile is mandatory during the course of treatment 
 Overt hypothyroidism seen in all patients who already had 
hypothyroidism due to thyroidectomy done previously but it is not seen in 
patients only on chemotherapy who did not undergo surgery. There is an 
increase levels of TSH in patients with therapy seen in thyroidectomy 
patients and the dosage of thyroxine replacement to be increased due to 
worsening of symptoms. Studies shows that increased TSH is due to 
imatinib therapy. But by discontinuing the drug, TSH levels have 
decreased.It indicates that the metabolism of thyroid hormone is altered by 
the imatinib. Most common mechanism hypothesized was iodine clearance 
in metabolism of thyroid hormone. 
 Therefore an challenge to oncologist to observe for clinical signs 
and symptoms of hypothyroidism and hyperthyroidism. Order for thyroid 
profile and treat accordingly with thyroid hormone replacement. 
Mandatory to do baseline thyroid function of the patients with CML on 
tyrosine kinase therapy before the start of the treatment, during the course 
of the treatment and after the therapy.  
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MATERIAL AND METHODS 
SELECTION OF VOLUNTERS: 
 On patients who have been confirmed to have Philadelphia 
chromosome positive chronic myeloid leukemicpatients, a retrospective 
follow up at hematology department Rajiv Gandhi government general 
hospital. Recommended thyroid profile to these patients before the start of 
imatinib treatment and monitor thyroid profile during the course of 
treatment after 6months of duration. 
STUDY CENTRE: 
Department of hematology,madras medical college and Rajiv Gandhi 
government general hospital, Chennai. 
DURATION OF THE STUDY: 
6 MONTHS 
STUDY DESIGN: 
 Observational study 
SAMPLE SIZE: 
 100 patients 
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DATA COLLECTION AND METHODS: 
        Blood sample taken for thyroid profile from already diagnosed  
CML patients in stable phase. Thyroid profile includes total T3,T4,TSH in 
op of hematology department. 
 Method used is Elisa and sensitivity is about 0.005mIu/l 
 Quantity  :  96 tests 
 Range   :  0.5 to 40microIu/ml 
 Sample volume :  50microL/well 
 Principal:  solid phase sandwich ELISA was named by Cali biotech 
TSH. The anti-TSH-HRP conjugate and samples are added to the wells 
which are coated with Streptavidin. HRPconjugate and unbound protein 
washed away through washed buffer, TSH of patients sample is 
sandwiched between two layers of antibodies. By the addition of substrate, 
the color intensity is directly proportional to the TSH concentration in the 
samples.  In relation to color intensity, the standard curve is prepared to 
the concentration of TSH. 
STORAGE AND STABILITY: 
 At 2 - 80 C products to be stored. 
  Stable for 24 months. 
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PRODUCT/PROCEDURE/INVESTIGATION DETAILS: 
 Total T3,T4,TSH 
 INCLUSION CRITERIA: Philadelphia chromosome positive 
CML on tyrosine kinase inhibitors for minimum period of 6 months, 
Normal and abnormal thyroid Profile. 
 EXCLUSION CRITERIA: Philadelphia chromosome negative 
patients, Blast crisis. 
STATISTICAL METHODS: 
 The statistical analysis is done based on paired t-test and p value is 
calculated using paired t- statistics 
SPONSORSHIP: 
No 
CONFLIT OF INTEREST 
None 
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OBSERVATION AND RESULTS 
 
STATISTICS AND ANALYSIS 
 
1. Age in years 
Age in years Frequency Percent 
Below 30 6 6.0 
31-40 13 13.0 
41-50 32 32.0 
51-60 28 28.0 
61-70 17 17.0 
Above 70 4 4.0 
Total 100 100.0 
 
 In the study conducted among 100 patients, thePrevalence of thyroid 
dysfunction is 32% in age group of 41 to 50 yrs. 
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2.  Sex distribution 
 
 Frequency Percent 
Valid 
Percent 
Cumulative 
Percent 
Valid 
Male 79 79.0 79.0 79.0 
Female 21 21.0 21.0 100.0 
Total 100 100.0 100.0  
 
 
 In the study conducted among 100 patients, Prevalence of thyroid 
dysfunction is 79% among males. 
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3. Thyroid Status - Before Therapy 
 
 Frequency Percent 
Valid 
Percent 
Cumulative 
Percent 
Valid 
Normal 91 91.0 91.0 91.0 
Hypothyroid 9 9.0 9.0 100.0 
Total 100 100.0 100.0  
 
 
In our study conducted among 100 patients,Thyroid profile before start 
of  treatment Results shows out of 100 patients, 91% are euthyroid and 9% 
are hypothyroid. 
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4. Thyroid Status - After Therapy 
 
 Frequency Percent 
Valid 
Percent 
Cumulative 
Percent 
Valid 
Normal 86 86.0 86.0 86.0 
Hypoth
yroid 
14 14.0 14.0 100.0 
Total 100 100.0 100.0  
      
 
 In our study conducted among 100 patients,Thyroid profile obtained 
after 6months duration of therapy 
 
 Results shows out of 100 patients 14% are hypothyroid and 86% are 
euthyroid. 
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T-Test 
5. Paired Samples Statistics 
 
 Mean Std. Deviation P value 
T3 - Before 
Therapy 
113.35 35.355 
0.074 
T3 - After 
Therapy 
108.22 34.199 
 
 
 In study group, T3 before and after  imatinib  therapy has no 
statistical significance.  
 
 
 
 
 
 
 
 
  
65 
 
 
6. Paired Samples Test 
 
 Paired Differences t df P value 
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Therapy - T3 
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5.13 9.805 .980 3.18 7.08 
5.23
2 
99 0.074 
 
 
 In study conducted among 100 patients,T3 before and after therapy 
regarding development of hypothyroidism by  imatinib therapy has no 
statistical significance. 
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T-Test 
7. Paired Samples Statistics 
 
 Mean N 
Std. 
Deviation 
Std. 
Error 
Mean 
P value 
Pair 1 
T4 - 
Before 
Therapy 
6.886 100 1.8637 .1864  
 
T4 - After 
Therapy 
6.386 100 1.9047 .1905 0.059 
 
   In our study, T4 before and after therapy has no statistical 
significance. 
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8. Paired Samples Test 
 
 
Paired Differences 
t 
p 
Value 
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Pair 
1 
T4 - 
Before 
Therapy - 
T4 - After 
Therapy 
.500 .6988 .0699 .361 .639 7.155 0.059 
 
 
In study group of 100 patients,T4 before and after therapy regarding 
development of hypothyroidism  by imatinib therapy has no statistical 
significance.  
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T-Test 
9. Paired Samples Statistics 
 
 Mean N 
Std. 
Deviation 
Std. 
Error 
Mean 
P value 
Pair 1 
TSH - 
Before 
Therapy 
3.616 100 1.3801 .1380 
 
 
TSH - 
After 
Therapy 
4.740 100 3.0356 .3036 0.016 
 
 In this study group, TSH before and after therapy has statistical 
significance, pvalue is 0.016 
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10. Paired Samples Test 
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-1.12
4 
2.0606 .2061 
-1.53
3 
-.715 0.016 99 0.016 
 
 In study group of 100 patients, TSH  before and after therapy 
regarding development of hypothyroidism due to imatinib therapy has 
statistical significance. 
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11.Crosstabs 
Thyroid Status - Before Therapy * Thyroid Status - After  
Therapy Crosstabulation 
 
Thyroid Status - 
Before Therapy 
 
 
 
 
Thyroid Status - 
After Therapy 
Total 
P value 
Normal 
Hypothy
roid 
 
Normal 
 
 
Count 86 5 91  
 
 
 
 
 
 
 
 
0.056 
% within Thyroid 
Status - Before 
Therapy 
94.5% 5.5% 100.0% 
% within Thyroid 
Status - After 
Therapy 
100.0% 35.7% 91.0% 
Hypothyroid 
 
 
Count 0 9 9 
% within Thyroid 
Status - Before 
Therapy 
.0% 100.0% 100.0% 
% within Thyroid 
Status - After 
Therapy 
.0% 64.3% 9.0% 
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Total 
Count 86 14 100 
% within Thyroid 
Status - Before 
Therapy 
86.0% 14.0% 100.0% 
% within Thyroid 
Status - After 
Therapy 
100.0% 100.0% 100.0% 
 
 Among 100 patients in the study, 
 Thyroid profiles before imatinib therapy resulted in 9%  
hypothyroid. 
 Thyroid profile during the course of imatinib therapy of more than 
6months duration resulted in 14% of hypothyroid. 
 Among 14% of hypothyroid, 5% of hypothyroid are diagnosed 
during therapy. 
 Imatinib therapy causes subclinical hypothyroid in only 5% of 
patients. 
 p value is 0.056 which has no statistical significant.  
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 Above graph represents,majority of the patients about 86% are 
euthyroid after imatinib therapy. 
 Out of 14% of patients, 9% are already diagnosed before therapy 
only 5% of patients developed subclinical hypothyroid (TSH between 5 to 
10, T4 & T3 - N) 
 Already diagnosed 9% hypothyroid patients developed overt 
hypothyroid. (TSH above 10, T4-I, T3-N) 
Thyroid Status - Before Therapy
HypothyroidNormal
Co
u
n
t
100
80
60
40
20
0
Thyroid Status - Aft
Normal
Hypothyroid
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12. Descriptives 
 
Descriptive Statistics 
 N 
Minim
um 
Maxim
um Mean 
Std. 
Deviation 
T3 - Before 
Therapy 
100 49 196 113.35 35.355 
T4 - Before 
Therapy 
100 3.9 11.7 6.886 1.8637 
TSH - Before 
Therapy 
100 .9 6.9 3.616 1.3801 
Valid N 
(listwise) 
100     
 
Mean value of T3 before imatinib therapy-113.35 
Mean value of T3 after imatinib therapy-108.22 
Mean value of T4before imatinib therapy-6.88 
Mean value of T4 after imatinib therapy-6.38 
Mean value of TSH before imatinib therapy-3.61 
Mean value of TSH after imatinib therapy-4.74 
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13. Descriptive Statistics 
 
 
N 
Minimu
m 
Maxim
um 
Mean 
Std. 
Deviation 
T3 - After 
Therapy 
100 46 185 108.22 34.199 
T4 - After 
Therapy 
100 3.1 10.9 6.386 1.9047 
TSH - After 
Therapy 
100 .9 13.8 4.740 3.0356 
Valid N 
(listwise) 
100     
 
 In this study conducted on 100 patients, Majority have Normal T3, 
T4,  and TSH. 
 Only 5% of patients have subclinical hypothyroid 
 9% of subclinical hypothyroid patientshave overt hypothyroid 
 Pvalue is 0.056 - No Statistical Significance.  
 
 
 
 
  
 
 
DISCUSSION 
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DISCUSSION 
 An observational study was conducted at department of hematology, 
Madras Medical College and Rajiv Gandhi General Hospital, Chennai for 
a period of one year duration. 
 Retrospectively chosen100 Philadelphia chromosome positive CML 
patients on tyrosine kinase inhibitors for minimum period of 6 months 
were followed up at the hematology department . 
 Participants eligible for the study are Philadelphia chromosome 
positive CML patients on tyrosine kinase inhibitors for minimum period of 
6months with both normal and abnormal thyroid status. From the study, 
participants who are excluded are CML in blast crisis and Philadelphia 
chromosome negative patients. Blood sample was collected to screen the 
Thyroid profile T3, T4,TSH in the patients before imatinib therapy and 
monitored during the course of therapy at minimum of 6 months duration. 
 Many studies have shown that tyrosine kinase inhibitors causes 
thyroid dysfunction in Ph chromosome positive CML patients. Our study 
was conducted on 100 patients to find the thyroid dysfunction in these 
patients. 
 Out of 100 patients before imatinib therapy, 9% showed subclinical 
hypothyroidism and 91% showed euthyroid status. After 6 months of 
treatment, 5% were hypothyroid out of 91% patients and 9% of Patients 
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with subclinical hypothyroidism had worsening of thyroid profile. It 
indicates that prevalence of thyroid dysfunction is minimal with imatinib 
therapy. Whereas patients with known subclinical hypothyroidism has 
increased thyroid dysfunction after the imatinib therapy. Thus there is a 
need to increase the dose of thyroxine in these hypothyroid patients. 
 Thus imatinib has effect on thyroid function or its metabolism 
because the TSH values is statistically increased in subclinical hypothyroid 
patients after imatinib therapy.  
 One study by Groot et al. reported that : Imatinib therapy does not 
cause thyroid dysfunction in euthyroid patients whereas already 
hypothyroid patients (included in this study with medullary thyroid 
carcinoma and thyroidectomised patients) had significant increase in TSH 
levels. As a result the need for levothyroxine dose to be increased in these 
patient as imatinib causes enzyme induction by clearance of 
nondeiodination. 
 Our study has a larger study population than the above study. They 
have monitored TFT only for 16 weeks of duration. But in our study we 
have included only imatinib among tyrosine kinase inhibitors due to only 
availability of the drug whereas in the above study all generations of 
tyrosine kinase inhibitors were used. 
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 Abraham etal.reported : that thyroid abnormalities in form of sub 
clinical hypothyroidism is more prevalent in women with CML in south 
India. 
 Foldeset el., stated:  that CML itself does not have any effect on 
thyroid function to results in hypothyroidism. 
 In another study by Jose’ Miguel Dora reported: that imatinib does 
not causes thyroid dysfunction in euthyroid patients. In this study 
conducted on 70 patients, the T3,T4, TSH were within the normal levels 
and already known hypothyroid patients were excluded. The mechanism of 
hypothyroidism was found to be that “imatinib induces conjugation of 
giucoronates and sulfates in liver”. TSH before therapy and sample size are 
limitation in this study. This study concluded that imatinib has no effect on 
thyroid dysfunction in euthyroid patients. 
 Multiple studies reported that, other tyrosine kinase inhibitors like 
sunitib, sorafenib, dastinib, pozatinib, nilotinib. sunitib are very potent to 
cause hypothyroidism within few weeks of therapy. About 85% of cases 
have been effected. 
 In our study, only 5% of euthyroid patients had subclinical 
hypothyroidism after imatinib therapy more than 6months  of duration. 
Whereas 9% of subclinical hypothyroid patients developed overt 
hypothyroidism after imatinib therapy. Rest 86%of patients remained 
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euthyroid after imatinib therapy for more than 6months duration of therapy. 
This study indicates that imatinib does not cause statistically significant 
thyroid dysfunction in euthyroid CML Ph chromosome positive patients. 
 Imatinib has minimal effects on peripheral metabolism of thyroid 
hormones causing the development of overt hypothyroidism in patients 
with subclinical hypothyroidism. Prevalence of hypothyroidism in 
imatinib treated CML Ph chromosome positive patients has statistical 
insignificance. Thus imatinib therapy is not associated with the 
development of hypothyroidism more than general population. 
 
  
  
 
 
CONCLUSION 
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CONCLUSION 
Although the incidence of hypothyroidism in our study population was 
insignificant the presence of statistically significant TSH increase makes it 
mandatory to screen thyroid profile in CML patients before the start of 
tyrosine kinase inhibitors .Monitor thyroid profile during the course of 
treatment and after the therapy, to look for thyroid dysfunction. In 
subclinical hypothyroid patients, strict regular follow up is 
recommended .Early diagnosis and treatment will improve the quality of 
life, survival and prognosis. 
 Discontinuation of imatinib therapy due to hypothyroidism is not 
encouraged. 
 
FUTURE SCOPE 
 Many studies to be encouraged to know thyroid dysfunction due to 
tyrosine kinase inhibitors. Studies related to duration, dosage of thyroid 
hormone replacement to be reported for the better quality of life in stable 
CML patients. In future, more studies are needed to support our findings. 
 
  
  
 
 
LIMITATIONS 
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LIMITATIONS 
 Small sample size, duration of study, no comparisons with other 
generations of tyrosine kinase inhibitors, relationship of thyroid 
dysfunction with duration and dosage of therapy, anti-thyroid antibodies . 
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ANNEXURES 
  
ABBREVIATIONS 
CML  : chronic myeloid leukemia 
Ph  : Philadelphia chromosome 
BCR  : Breakpoint cluster region gene 
ABL  : Abelson gene 
STAT        :   Signal transducers and activators of transcription. 
PI3-K         :   Phosphatidylinositol 3-kinase 
GM-CSF      :   Granulocyte macrophage colony stimulating factor. 
SCT           : Stem cell transplant 
FISH           :     fluorescence insitu Hybridization 
RT-Q PCR : real time quantitative PCR 
VEGFR        : vascular endothelial growth factor receptors 
CMPD         : chronic myeloproliferative disease. 
GRB-2         : growth factor receptor bound protein. 
TKI            :    Tyrosine kinase inhibitors 
CBA  :     chromosome banding analysis 
 
PROFORMA 
 
 
NAME OF THE PATIENT : 
AGE / SEX    : 
IP/OP NUMBER   : 
OCCUPATION   : 
ADDRESS    : 
 
 
CONTACT NUMBER  : 
COMPLAINTS   : 
 
 
PAST HISTORY   : 
 
 
TREATMENT HISTORY : 
 
DRUG ALLERGY : 
GENERAL EXAMINATION : 
 
 
VITALS     : 
 
SYSTEMIC EXAMINATION 
CARDIOVASCULAR SYSTEM: 
 
RESPIRATORY SYSTEM   : 
 
ABDOMEN         : 
 
CENTRAL NERVOUS SYSTEM 
THYROID PROFILE: 
LIVER FUNCTION TESTS: 
 
 
ULTRASOUND ABDOMEN: 
ULTRASOUND NECK: 
COAGULATION PROFILE: 
DATE OF STARTING THYROID PROFILE: 
DATE OF ENDING THYROID PROFILE     : 
TOTAL DURATION : 
COMPLIANCE  : 
 
SIDE EFFECTS  

  

 
 
  
 
 
 
 
MASTER CHART 
 
S.NO AGE/SEX BEFORE IMATINIB THERAPYPRETREATMENT DURATION OF IMATINIB THERAPY AFTER IMATINIB THERAPY POST TREATMENT
T3 T4 TSH THYROID STATUS T3 T4 TSH THYROID STATUS
(60-200) (4.5-12) (0.30-5.5) (60-200) (4.5-12) (0.30-5.5)
1 56/M 117 8.2 3.2 NORMAL 11MONTHS 122 7.8 3.7 NORMAL
2 49/M 89 6.4 2.8 NORMAL 9 MONTHS 87 5.9 3 NORMAL
3 52/F 76 5.8 1.3 NORMAL 11MONTHS 78 5.4 1.5 NORMAL
4 42/M 123 7.8 4.1 NORMAL 24MONTHS 125 7.6 4.6 NORMAL
5 59/M 189 9.6 4.6 NORMAL 19 MONTHS 176 9.1 5 NORMAL
6 47/M 93 5.9 3.9 NORMAL 8MONTHS 94 5.4 3.2 NORMAL
7 32/F 104 7.2 2.8 NORMAL 11 MONTHS 98 7.1 2.7 NORMAL
8 43/M 70 10.3 4.5 NORMAL 23 MONTHS 52 8.9 7.1 HYPOTHYROID
9 65/M 154 6.1 1.3 NORMAL 7M0NTHS 143 5.1 1.9 NORMAL
10 34/M 167 5.8 2.8 NORMAL 8MONTHS 170 5.9 2.8 NORMAL
11 43/F 79 4.9 0.9 NORMAL 9MONTHS 81 4.7 1.2 NORMAL
12 65/M 156 5.9 2.9 NORMAL 15MONTHS 160 6.1 3.2 NORMAL
13 52/M 76 4.6 1.1 NORMAL 28MONTHS 82 4.9 1.8 NORMAL
14 41/M 178 9 4.9 NORMAL 9MONTHS 181 10.6 5.2 NORMAL
15 65/F 98 6.6 1.9 NORMAL 9MONTHS 109 6.9 2.9 NORMAL
16 59/F 161 8.3 4.8 NORMAL 21MONTHS 168 10.6 5.9 NORMAL
17 39/M 92 6.1 4.9 NORMAL 13MONTHS 98 5.3 4.8 NORMAL
18 61/M 183 11.2 5.1 NORMAL 11MONTHS 179 10.9 5.3 NORMAL
19 29/M 121 7.1 3.9 NORMAL 21MONTHS 119 6.2 3.3 NORMAL
20 72/M 116 4.8 1.6 NORMAL 9MONTHS 98 4.5 0.9 NORMAL
21 57/M 72 4.8 4.1 NORMAL 18MONTHS 46 3.6 7.9 HYPOTHYROID
22 49/M 48 4.5 6.1 HYPOTHYROID 27MONTHS 34 4.1 12.9 HYPOTHYROID
23 45/F 87 8.1 4.6 NORMAL 7M0NTHS 82 7.5 3.9 NORMAL
24 52/F 67 4.7 1.9 NORMAL 12MONTHS 71 5.1 2.6 NORMAL
25 36/M 87 5.7 2.3 NORMAL 13MONTHS 84 4.9 2.9 NORMAL
26 42/M 113 8.4 1.4 NORMAL 10MONTHS 109 6.9 2.3 NORMAL
27 65/M 147 7.3 3.1 NORMAL 8MONTHS 137 6.9 2.5 NORMAL
28 50/M 196 9.6 4.3 NORMAL 7MONTHS 173 8.7 3.9 NORMAL
29 40/M 123 7.9 3.2 NORMAL 10MONTHS 119 7.1 2.9 NORMAL
30 53/M 109 5.3 2.9 NORMAL 14MONTHS 102 5.1 1.9 NORMAL
31 49/M 154 10.6 4.2 NORMAL 21MONTHS 160 9.8 4.7 NORMAL
32 52/F 78 6.1 2.3 NORMAL 9MONTHS 81 6.6 2.8 NORMAL
33 57/M 89 5.9 2.7 NORMAL 11MONTHS 93 5.1 2.1 NORMAL
34 46/M 92 8.1 3.1 NORMAL 15MONTHS 89 7.8 2.9 NORMAL
35 39/F 72 5.1 1.1 NORMAL 16M0NTHS 69 4.9 1.2 NORMAL
36 41/M 110 9.8 1.4 NORMAL 9MONTHS 110 8.9 1.2 NORMAL
37 39/M 161 11.7 4.1 NORMAL 16M0NTHS 121 10.3 3.9 NORMAL
38 47/M 112 7.8 2.9 NORMAL 15MONTHS 110 7.2 2.1 NORMAL
39 43/M 92 6.8 3.3 NORMAL 12MONTHS 85 6.1 2.5 NORMAL
40 52/M 121 8.9 3.9 NORMAL 13MONTHS 91 5.9 4.1 NORMAL
41 49/M 161 8.6 4.1 NORMAL 11MONTHS 154 8.1 4.7 NORMAL
42 54/M 98 7.9 3.6 NORMAL 24MONTHS 78 6.5 8.3 HYPOTHYROID
43 29/M 87 10.1 3.3 NORMAL 9MONTHS 81 9.4 5.1 NORMAL
44 67/M 172 8.9 4.6 NORMAL 13MONTHS 161 8.5 5.1 NORMAL
45 50/M 142 6.9 3.7 NORMAL 7MONTHS 136 6.1 4.1 NORMAL
46 28/M 93 6.1 4.1 NORMAL 1OMONTHS 89 5.6 4.7 NORMAL
47 30/F 84 8.7 3.9 NORMAL 12MONTHS 79 7.4 4.9 NORMAL
48 51/M 156 9.3 4.9 NORMAL 21MONTHS 143 8.4 5.1 NORMAL
49 67/F 119 6.9 3.7 NORMAL 20MONTHS 112 5.9 4.2 NORMAL
50 49/M 150 9.4 2.2 NORMAL 11MONTHS 143 8.9 3.8 NORMAL
51 37/M 71 4.7 5.6 HYPOTHYROID 21MONTHS 42 3.6 13.7 HYPOTHYROID
52 52/F 128 5.9 4.1 NORMAL 10MONTHS 116 5.6 4.6 NORMAL
53 41/M 171 7.3 3.4 NORMAL 28MONTHS 163 6.9 4.1 NORMAL
54 67/M 121 5.8 2.8 NORMAL 13MONTHS 119 4.9 3.9 NORMAL
55 56/M 146 7.2 3.8 NORMAL 21MONTHS 132 7.8 3.9 NORMAL
56 43/M 121 6 3.1 NORMAL 12MONTHS 112 6.3 3.7 NORMAL
57 51/F 137 8.4 3.9 NORMAL 11MONTHS 121 7.2 3.1 NORMAL
58 62/F 141 7.3 3.1 NORMAL 8MONTHS 118 6.9 2.9 NORMAL
59 54/M 79 5.2 4.7 NORMAL 23MONTHS 76 5.1 5.2 NORMAL
60 68/M 92 7.2 4.9 NORMAL 19MONTHS 85 6.2 5.1 NORMAL
61 42/M 56 4.5 6.9 HYPOTHYROID 36MONTHS 42 3.9 13.6 HYPOTHYROID
62 76/M 78 5.9 4.6 NORMAL 41MONTHS 82 6.3 4.1 NORMAL
63 55/M 88 5.9 3.9 NORMAL 11MONTHS 91 6.1 4.8 NORMAL
64 44/M 78 5.8 1.1 NORMAL 9MONTHS 72 5.1 1.9 NORMAL
65 52/M 118 6.2 4.9 NORMAL 10M0NTHS 89 5.1 8.3 HYPOTHYROID
66 39/M 161 8.3 5.1 NORMAL 8MONTHS 165 8.1 5.1 NORMAL
67 40/M 123 6.5 2.8 NORMAL 15MONTHS 119 6.1 3.1 NORMAL
68 69/M 92 4.9 1.6 NORMAL 9MONTHS 89 4.2 3.1 NORMAL
69 49/M 87 5.9 2.1 NORMAL 18MONTHS 82 4.7 3.1 NORMAL
70 72/M 167 10.9 3.3 NORMAL 12MONTHS 148 9.2 7.2 HYPOTHYROID
71 49/F 101 4.9 2.3 NORMAL 7MONTHS 98 4.2 3.3 NORMAL
72 61/M 92 5.6 2.1 NORMAL 16M0NTHS 85 6.1 4.1 NORMAL
73 55/M 111 4.4 2.7 NORMAL 18MONTHS 110 4.2 3.1 NORMAL
74 33/F 99 5.9 4.2 NORMAL 21MONTHS 95 5.5 5.1 NORMAL
75 41/F 63 4.2 5.9 HYPOTHYROID 9MONTHS 51 3.3 9.3 HYPOTHYROID
76 63/M 143 7.9 3.8 NORMAL 13MONTHS 136 7.2 4.1 NORMAL
77 39/M 156 8.4 4.1 NORMAL 22MONTHS 145 7.9 4.5 NORMAL
78 45/M 54 3.9 6.2 HYPOTHYROID 29MONTHS 42 3.7 10.7 HYPOTHYROID
79 62/M 99 6.7 3.5 NORMAL 12MONTHS 92 6.2 4.5 NORMAL
80 76/M 68 7.8 4.4 NORMAL 32MONTHS 71 7.3 4.5 NORMAL
81 36/F 49 3.9 6.9 HYPOTHYROID 18MONTHS 41 3.2 11.3 HYPOTHYROID
82 52/M 118 6.4 4.3 NORMAL 23MONTHS 121 6.4 4.8 NORMAL
83 48/M 131 5.9 3.8 NORMAL 16M0NTHS 129 5.4 4.9 NORMAL
84 51/M 121 8.9 4.1 NORMAL 10M0NTHS 111 8.2 4.9 NORMAL
85 64/M 190 7.9 3.9 NORMAL 19MONTHS 185 7.1 4.1 NORMAL
86 42/M 55 3.9 5.5 HYPOTHYROID 18MONTHS 48 3.2 11.4 HYPOTHYROID
87 29/F 78 4.8 4.2 NORMAL 8M0NTHS 76 5.1 5.1 NORMAL
88 54/M 102 4.9 3.5 NORMAL 12MONTHS 111 4.2 4.2 NORMAL
89 46/F 48 3.9 5.8 HYPOTHYROID 22MONTHS 39 3.7 12.8 HYPOTHYROID
90 61/M 87 7.5 4.1 NORMAL 7MONTHS 89 7.2 4.8 NORMAL
91 44/M 156 10.3 3.7 NORMAL 12MONTHS 129 10.1 4.9 NORMAL
92 51/M 132 7.5 3.2 NORMAL 9MONTHS 128 7.6 3.8 NORMAL
93 49/M 176 11.6 1.1 NORMAL 6MONTHS 165 10.9 1.9 NORMAL
94 58/M 113 6.8 1.8 NORMAL 11MONTHS 110 6.4 2.4 NORMAL
95 59/M 109 5.9 2.1 NORMAL 12MONTHS 107 5.9 3.6 NORMAL
96 68/M 49 4.4 5.5 HYPOTHYROID 33MONTHS 39 4.1 13.6 HYPOTHYROID
97 52/M 96 4.9 4.1 NORMAL 8MONTHS 110 4.5 4.3 NORMAL
98 30/M 135 6.8 3.3 NORMAL 11MONTHS 130 6.5 4.2 NORMAL
99 42/F 95 4.9 2.7 NORMAL 12MONTHS 86 4.5 3.6 NORMAL
100 56/M 97 5.1 4.8 NORMAL 7MONTHS 107 4.9 5.1 NORMAL
  
 
 
  
 
 
 
 
 
 
 
 
